New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Keynote Presentation. Dr. William Dahut discussed how ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

The Elekta Unity MR-LINAC system, used at Allegheny General Hospital, combines MRI imaging with radiation therapy to target cancerous cells with pinpoint precision.

New research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

A new research paper was published in Aging (Aging-US) on January 3, 2025, in Volume 17, Issue 1, titled "Characterization of DNA methylation clock algorithms applied to diverse tissue types." ...

Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5BOCA RATON, ...

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced ...

Veracyte, Inc. , a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Danish ...